NCT02050178View on ClinicalTrials.gov

Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

June 15, 2017

Study Completion Date

June 15, 2017

Conditions
Pancreatic CancerStage IV Pancreatic Cancer
Interventions
DRUG

OMP-54F28, Nab-Paclitaxel and Gemcitabine

Trial Locations (5)

19111

Fox Chase Cancer Center, Philadelphia

37232

Vanderbilt University Medical Center, Nashville

46202

Indiana University Simon Cancer Center, Indianapolis

80045

University of Colorado Hospital Anschutz Cancer Pavilion, Aurora

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY